Orphan/Rare Disease Drugs where we play in are exempt (currently), and there are articles that recasts this as a positive for discovery companies such as ours, as big Pharma will seek to redeploy resources as a result fueling future M&A activity.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.050(4.17%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.15 | $146.7K | 125.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71742 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 11949 | 2 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |